Neonatal Point of Care Testing Market

SKU: DMMD4127 | Last Updated On: Sep 25 2022 | Available Formats

>Neonatal Point of Care Testing Market Expected to reach a high CAGR 10.8% By 2029:

Neonatal Point Of Care Testing Market is Segmented By Product(Instruments and Assay), By End-User(Hospitals, Diagnostic centres, Maternity & Speciality Clinics and Other), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029

Neonatal point of care testing market is estimated to reach at a high CAGR 10.8% during the forecast period (2022-2029). 

Point-of-care testing (POCT) is a type of testing in which the analysis is carried out where the patient receives healthcare. The factors driving the global neonatal point of care testing market are the rising prevalence of rare diseases and the increasing demand for better healthcare facilities.

The rising prevalence of rare diseases is estimated to drive the neonatal point of care testing market

If known, effective health measures are offered before delivery and during the first week of life, up to two-thirds of neonatal deaths can be avoided. About 3.3 million of the 8.2 million children under the age of five who die each year do so in the neonatal period, or the first four weeks of life. Neonatal disorders refer to a newborn's natural body, organs, and function being disrupted. Obstetricians have a critical role in reducing newborn problems. Prematurity, respiratory failure, birth trauma, congenital abnormalities, neonatal infection, and infant haemolytic diseases are the most prevalent neonatal ailments. The importance of preventive obstetrics in decreasing these illnesses cannot be overstated. Prematurity can be avoided with regular antenatal check-ups, a well-balanced diet, iron and folic acid supplements, and avoiding multiple pregnancies.

The oxygen-carrying capacity and oxygen saturation of haemoglobin and cardiac and respiratory function all influence oxygen delivery to the tissues. Hypoxia is linked to pulmonary hypertension, reduced pulmonary blood flow, acidosis, and organ damage. It can be caused by a lack of cardiac output, congenital heart disease, lung disease, anaemia, or haemoglobin variations. Hyperoxia, which can occur when oxygen is given to a premature baby, has been linked to an increased risk of retinopathy of prematurity and other kinds of oxygen poisoning. The therapeutic goal is to provide adequate oxygen delivery without undue strain on organs like the lungs and retina. Intensive laboratory testing, including frequent blood gas analysis, is required for preterm, very-low-birth-weight neonates during the first few weeks of life. The weekly blood loss related to phlebotomy for blood testing has been estimated to account for up to 30% of the total blood volume of these tiny, vulnerable newborns. The anaemia caused by phlebotomy cannot be sustained, and red-cell transfusion is frequently required to treat the anaemia. Blood gas analyzers that use point-of-care testing (POCT) use small sample quantities and hence can reduce the prevalence of phlebotomy-associated anaemia in newborns. Clinicians in a California neonatal critical care unit were able to measure the influence of a POCT analyzer on the usage of red-cell transfusions after it was introduced. On 100 litres of whole blood, the newly installed POCT analyzer measures blood gases, haemoglobin, hematocrit, sodium, potassium, and ionised calcium all at the same time.

The increasing demand for better healthcare facilities is estimated to drive the global neonatal point of care testing market

According to WHO, Low and middle-income nations account for the great majority of neonatal fatalities. By achieving high coverage of excellent antenatal care, competent birth care, postnatal care for mother and baby, and treatment of small and sick infants, it is possible to increase newborn survival and health and reduce unnecessary stillbirths. Midwife-led continuity of care (MLCC) can prevent premature births by up to 24 per cent in settings with well-functioning midwife programmes. MLCC is a model of care in which the same woman is cared for by a midwife or a team of midwives throughout her pregnancy, labour, and the postpartum period, with medical assistance as needed. With the rise in facility deliveries (almost 80% worldwide), there is an excellent chance to provide vital infant care and identify and manage high-risk newborns.

On the other hand, few mothers and newborns stay at the facility for the full 24 hours after birth, which is when difficulties are most likely to occur. Furthermore, premature discharge from the hospital, access restrictions, and delays in obtaining care cause far too many neonates to die at home. The four recommended postnatal care contacts, administered at a health institution or via home visits, are critical in reaching these newborns and their families.

On December 12, 2019, the first test to aid in newborn screening for Duchenne Muscular Dystrophy (DMD), a rare genetic illness that causes progressive muscle degeneration and weakening, was approved by the US Food and Drug Administration.

The lack of knowledge and its drawbacks is estimated to hamper the neonatal point of care testing market

Point-of-care (POC) testing is subject to the same, if not more, types of interference as Central Laboratory (CL) testing. Because of analytical, interpretation, and reporting problems, POC tests may have increased imprecision and lower accuracy. Cross-reactants, oxidant/reductant, hematocrit, icterus, turbidity, and other factors can interfere with metabolites (including glucose) POC testing. POC immunoassays tests such as drugs of abuse, cardiac indicators, diabetes markers, pregnancy testing, infectious disease tests, and other tests may produce false findings due to these same factors, as well as heterophilic antibody and biotin interference. Pre-analytical mistakes that affect CL testing also impair POC testing. Poorly trained non-laboratory operators cause inaccuracy in all POC assays, including electrolytes, blood gas, and coagulation metres.

Diagnostic laboratories are unavailable to poor rural communities in low- and middle-income countries (LMICs). Until recently, this meant they couldn't be tested for asymptomatic diseases like HIV or syphilis and could only be treated syndromically when symptoms like fever appeared. This is no longer the case. Simple, rapid, and economical point-of-care tests (POCTs), which do not require electricity, a laboratory, or highly trained staff, are already accessible and frequently utilised for various prevalent illnesses in LMICs. Every year, more than half a million stillbirths or neonatal deaths are caused by syphilis in pregnancy. If all pregnant women were tested for syphilis and given a single dosage of penicillin before the third trimester, these deaths might be avoided. Hence, the lack of knowledge about neonatal point of care testing and its drawbacks is assumed to hamper the market.

COVID-19 Impact Analysis

COVID-19 has affected the healthcare industry moderately. To stop its spread, government-imposed lockdown. People are fearful they may experience occupational effects and negative health from the COVID-19 pandemic. The neonatal point of care testing has been carried out even during the pandemic. This has affected the neonatal care point of care testing market moderately due to limitations to avoid transmission of COVID.

Neonatal Point Of Care Testing Market Segment Analysis

The instruments segment is expected to dominate the neonatal point of care testing market

Diagnostic results are obtained using point of care (POC) diagnostic devices when the patient is present or close by. POC diagnostic devices are used at doctors' offices, hospitals, and patients' homes to respond immediately to various medical tests. POC diagnostic equipment is used to check blood sugar and cholesterol levels, analyse electrolytes and enzymes, test for abuse and infectious diseases drugs, and perform a pregnancy test. POC diagnostic devices can also perform blood gases, cardiac markers, and faecal occult blood tests.

The ABL90 FLEX PLUS blood gas analyzer is designed for point-of-care testing in high-volume clinical settings such as the emergency room, intensive care unit, neonatal intensive care unit, or delivery room, where quick results from a small blood sample are critical for making critical diagnostic decisions. At ISNS 2018, Labsystems Diagnostics Oy increased its newborn screening (NBS) products by launching six new high-quality NBS solutions. With this announcement, the brand continues on its path to becoming the world's leading provider of newborn screening services.

On June 14th, 2021, Hemex Health announced the release of its first virtual upgrade to its Gazelle platform and Sickle Cell Disease test, which extends the patient age range from 6 weeks and up to all ages, including infants. Printing upgrades and a range of ease-of-use features are included in the free upgrade for Gazelle users.

Neonatal Point Of Care Testing Market



Market CAGR


Segments Covered

By Product, By End-User, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

Neonatal Point Of Care Testing Market Geographical Analysis

North America region is estimated to dominate the global neonatal point of care testing market

With the increased childbirths and test approvals, this region is estimated to drive the neonatal point of care testing market. In the U.S overall, about 3.6 million babies were born in 2020. Most babies admitted to the NICU are premature (born before 37 weeks of pregnancy), have a low birth weight (less than 5.5 pounds), or have a medical condition that needs extra attention. In the United States, around half a million babies are born prematurely. Many of these infants were born with low birth weights. NICU admissions are common for twins, triplets, and other multiples. This is because they are typically born earlier and smaller than single-birth kids. The NICU also provides care for babies with respiratory difficulties, cardiac problems, infections, or birth deformities.

On January 14th, 2019, The Amplatzer PiccoloTM Occluder, the world's first medical device, can be implanted in the tiniest babies, utilising a minimally invasive method to treat patent ductus arteriosus PDA, has been authorised by the US Food and Drug Administration (FDA). The Amplatzer Piccolo, a device the size of a small pea, now gives hope to premature infants and newborns who require corrective treatment but are resistant to medical treatment and are at high risk of undergoing corrective surgery.

Neonatal Point Of Care Testing Market Competitive Landscape

The global neonatal point of care testing market is highly competitive with the high demand for newborn screening product launches by key players.

The major key players in the Global Neonatal Point of Care Testing Market are PerkinElmer, Inc., Trivitron Healthcare, Natus Medical Incorporated, Medtronic Plc, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., GE Healthcare (General Electric Company), ZenTech S.A., Mp Biomedicals, Baebies, Inc., Masimo, Evancare Medical (Nantong) Co., Ltd., Shenzhen Uni-Medica Technology Co., Ltd. and ShenZhen CAS-Envision Medical Technology Co., Ltd.

PerkinElmer, Inc.

Overview: PerkinElmer helps scientists, researchers, and physicians tackle their most pressing problems in science and medicine. They bring distinctive solutions to the diagnostics, life sciences, food, and applied markets, with a goal centred on innovating for a healthier world. The company forms strategic partnerships with customers to provide them with earlier and more accurate insights based on their deep market knowledge and technical skills.

Product Portfolio: The company focuses on diagnostics, life science research, food, environmental and industrial testing. Its capabilities include detection, imaging, informatics, Key Development: On December 13th 2019, PerkinElmer, Inc., their GSP® Neonatal Creatine Kinase –MM (CK-MM) kit was approved by the US Food and Drug Administration (FDA). This is the first commercially accessible assay for detecting Duchenne muscular dystrophy in infants (DMD). GSP® Neonatal Creatine Kinase –MM (CK-MM) kit has been approved by the United States Food and Drug Administration (FDA). This is the first commercially accessible assay for detecting Duchenne muscular dystrophy in infants.

Frequently Asked Questions

What is the Projected CAGR value of the Neonatal Point Of Care Testing Market?

Neonatal Point Of Care Testing Market is expected to grow at a CAGR of 10.8% during the forecasting period 2022-2029.

Which region controlled the global market during 2022-2029?

North America region Controls the Neonatal Point Of Care Testing Market during 2022-2029

Which is the fastest growing region in the Neonatal Point Of Care Testing Market?

Among all regions, Asia Pacific is the fastest growing market share during the forecast period 

Trending Topics

Neonatal Biotinidase Treatment Market

Neonatal Intensive Care Unit Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*

Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!